Note: Descriptions are shown in the official language in which they were submitted.
CA 022l07ll l997-07-l6
W O 96/23463 PCTrUS~G/0~501
~ A~) n~L~L FOFUrnI~TION
r
The present invention provides a novel transdermal
formulation containing the pharmaceutically active compound
3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-
methylpyridine (xanomeline).
Xanomeline, described in U.S. Patent No. 5,043,345
('345), is a compound having muscarinic activity which can be
useful for the treatment of Alzheimer's Disease. As set
forth in the '345 patent, xanomeline can be prepared in a
15 solid form for oral use, in the form of suppositories for
rectal administration, or in the form of sterile injectable
solutions for parenteral use. A formulation for a typical
tablet is provided; however, the patent does not suggest that
it would be possible or desirable to prepare a transdermal
20 xanomeline patch formulation.
Applicants have discovered that the transdermal
xanomeline patch formulation of this invention provides
suprising beneficial effects. The present invention provides
a method for treating Alzheimer's disease with fewer side
25 effects than are typically associated with muscarinic
agonists like xanomeline.
The transdermal formulation of this invention provides
consistent dosage of the active ingredient, achieves
30 sustained plasma concentration of the pharmaceutically active
agent, and encourages patient compliance.
.
The present invention provides a transdermal
xanomeline patch formulation comprising an effective amount
of xanomeline, from 0.1 to 10 parts by weight azone, from 30
to 69.8 parts ethanol, 29 to 50 parts by weight water, from O
CA 02210711 1997-07-16
W 096/23463 PCT~US96/00504
--2--
to 30 parts by weight propylene glycol, and 1 to 5 parts by
weight Klucel HF.
Further, there is provided a transdermal xanomeline
patch formulation comprising an effective amount of
xanomeline and from about 70 to 99.8~ acrylate adhesive.
There is provided a transdermal patch wherein xanomeline is
intimately distributed in a matrix.
Additionally, there is provided a transdermal
xanomeline patch formulation comprising an effective amount
of xanomeline, from 85 to 97 parts by weight ethanol and from
2 to 14.9 parts Klucel HF.
Finally, there is provided a method for treating
Alzheimer's disease comprising administering xanomeline
transdermally using a patch formulation.
As used herein "xanomeline" shall refer to the free
base, a pharmaceutically acceptable salt or solvate thereof.
The free base is preferred. The transdermal xanomeline patch
formulations of the present invention provide surprising
beneficial properties. The xanomeline tablet was associated
with undesired parasympathomimetic effects when administered
to humans. Applicants have discovered that the transdermal
patch formulation can minimize such effects while providing
higher sustained plasma levels of the pharmaceutically active
agent.
Although the transdermal patch formulations claimed
herein are preferred for the transdermal delivery of
xanomeline, other transdermal formulations may be employed.
Percutaneous or transdermal delivery of pharmacologically
active agents has become feasible in recent years largely due
to vehicles therefor which allow increased permeation of said
agents into the body surface to which applied. Such agents
which may be useful for the preparation of a xanomeline
transdermal patch formulation include, but are not
necessarily limited to, dimethylsulfoxide (U.S. Patent No.
3,551,554); various 1-substituted azacycloalkan-2-ones such
CA 02210711 1997-07-16
W O 96123463 PCTrUS96/00504
-3-
as azone (U.S. Patent Nos. 4,562,075, 4,405,616, 4,326,893
and 3,989,816); sugar esters in combination with sulfoxide or
phosphine oxide (U.S. Patent Nos. 4,130,667, 4,130,643,
4,046,886, 3,952,099, and 3,896,238); lower alkyl amides
(U.S. Patent No. 3,472,931); certain aliphatic sulfoxides
(U.S. Patent No. 3,903,256); a composition containing
glycerol monooleate, ethanol and isopropyl myristate (U.S.
Patent 4,335,115); a binary mixture of 1-
dodecylazacycloheptan-2-one and a compound selected from a
diol or a second N-substituted azacycloalkyl-2-one (U.S.
Patent Mo. 4,557,934); and polyethylene glycol monolaurate
(U.S. Patent No. 4,568,343). U.S. Patent Nos. 3,551,554,
4,562,075, 4,405,616, 4,326,893, 3,989,816, 4,130,667,
4,130,643, 4,046,886, 3,952,099, 3,896,238, 3,472,931,
3,903,256, 4,335,115, 4,557,934, and 4,568 343 are hereby
incorporated by reference in their entirety.
It is contemplated that the transdermal patch
formulations of this invention will find utility in both
humans and animals, i.e., will have both medical and
veterinary applications for providing increased percutaneous
absorption of the pharmaceutically active agent. As used
herein, the term "percutaneous" refers to the passage of such
agents through skin (typically intact).
The transdermal formulations of the present
invention may be administered using a variety of devices
which have been described in the art. For example, such
devices include, but are not limited to those described in
U.S. Patent Nos. 3,598,122, 3,598,123, 3,710,795, 3,731,683,
3,742,951, 3,814,097, 3,921,636, 3,972,995, 3,993,072,
3,993,073, 3,996,934, 4,031,894, 4,060,084, 4,069,307,
4,077,407, 4,201,211, 4,230,105, 4,292,299, and 4,292,303
each of which is hereby incorporated by reference in its
entirety. The dosage forms of the present invention may
incorporate certain pharmaceutically acceptable excipients
- 35 which are conventional in the art. These include, but are
CA 022l07ll l997-07-l6
W O 96123463 PCT~US9CJ0~'01
not limited to, gelling agents, cream and ointment bases, and
the like.
Xanomeline shall be present in the claimed dosage
forms in an effective amount. The term "an effective amount"
shall refer to an amount calculatecl to achieve and maintain
blood levels which will bring about the desired beneficial or
therapeutic effect over the period of time desired. These
amounts will vary depending the amount of pharmacologically
active agent required to achieve the desired beneficial or
therapeutic effect, whether one or more patches will be
administered simultaneously the specific formulation of the
patch, the age and condition of the patient to be treated,
and the like. Such conventional dosage titration techniques,
familiar to the skilled artisan, may be utilized to determine
the amount of xanomeline present in the ultimate
pharmaceutical dosage form for any specific situation.
The pharmacologically active xanomeline is
administered by known techniques such as placing the patch
containing said agent and transdermal formulation therefor on
a body surface and maintaining said source on said body
surface in agent and composition transmitting relation
thereto.
One of the transdermal xanomeline patch
formulations utilizes ethanol, water, azone, and optionally
propylene glycol to enhance the permeation of the
pharmacologically active xanomeline. As noted supra., azone
is known to be useful for transdermal permeation enhancement
and is chemically l-dodecylazacyloheptan-2-one. Azone can be
prepared as described in U.S. Patent No. 4,316,893, hereby
incorporated by reference.
Formulation of the claimed compositions may be
achieved by conventional methods, as by the simple mixing of
all components thoroughly. The artisan will appreciate that
compositions containing diols other than propylene glycol and
alcohols other than ethanol (i.e., 2-propanol) may find
utility in transdermal xanomeline compositions as a component
:
CA 02210711 1997-07-16
W 096t23463 PCTAUS~5~00'04
of the formulation. To the extent that such formulation
exhibits the characteristics of the present compositions,
such formulations are considered to fall within the scope of
the present invention.
The present invention provides a ~ransdermai
xanomeline patch formulation comprising an effective amount
of xanomeline, from 0.1 to 10 parts by weight azone, from 30
to 69.8 parts ethanol, 29 to 50 parts by weight water, from 0
to 30 parts by weight propylene glycol, and 1 to 5 parts by
weight Klucel HF. Preferred ranges for the formulation
include from 2 to 4 parts by weight azone, from 30 to 55
parts by weight ethanol, from 0 to 20 parts by weight
propylene glycol, from 35 to 45 parts water, and from 2.5 to
3.5 parts Klucel HF. One preferred embodiment is to omit
propylene glycol from the formulation.
There is provided a transdermal formulation patch
wherein an effective amount of xanomeline is intimately
distrubuted in a matrix. One such preferred matrix is a
pressure sensitive adhesive.
Further, there is provided a transdermal xanomeline
patch formulation comprising an effective amount of
xanomeline and from about 50 to 99.9% by weight acrylic
adhesive. A preferred range of acrylic adhesive comprises
from about 65 to about 99.8~ by weight acrylic adhesive. A
further preferred range of acrylic adhesive comprises from
about 70 to about 98% by weight acrylic adhesive. Another
preferred range for the acrylate adhesive is from about 80 to
98 parts by weight. The acrylate adhesive is commercially
available and may be purchased for example, from the National
Starch and Chemical Corporation, Bridgewater, New Jersey
08807, catalog number 80-1054. The acrylate adhesive
typically contains 48% solids in 33% ethyl acetate/28%
heptane/34~ isopropanol/5~ toluene by weight.
Additionally, there is provided a transdermal
xanomeline patch formulation comprising an effective amount
of xanomeline, from 85 to 97 parts by weight ethanol and from
CA 02210711 1997-07-16
W 096/23463 PCTrUS~G/0~'01
2 to 14.9 parts Klucel HF. Klucel HF is a commercially
available gelling agent. For example, Klucel HF may be
purchased from Aqualon. Other appropriate gelling agents can
be selected by the skilled artisan. Preferred ranges for the
formulation are 92 to 96 parts by weight ethanol and 2.5 to
3.5 parts Klucel HF or other appropriate gelling agent.
Another preferred range for such formulations comprises from
about 93 to about 95 parts by weight ethanol and from about 3
to about 3.5 parts gelling agent.
The compound xanomeline can be prepared as
described in U.S. Patent No. 5,043,345 Sauerberg et. al.
('345) which is hereby incorporated by reference in its
entirety. As disclosed in the '345 patent xanomeline can be
use~ul for the treatment of Alzheimer's disease, severe
painful conditions, glaucoma, and for the stimulation of
cognitive function of the forebrain and hippocampus of
mammals.
Xanomeline tablet formulation has been administered
to mild and moderately severe Alzheimer's Disease patients.
Such tablet formulation of xanomeline was associated with
undesired parasympathomimetic effects when administered to a
group of subjects. Surprisingly, the presently claimed
transdermal formulations of xanomeline can minimize or
eliminate such effects while maintaining a consistent,
desirable plasma concentration of the pharmacologically
active agent.
This invention provides a method for treating a
condition associated with modulation of a muscarinic receptor
with m;nim~l or no parasympathomimetic effects comprising
administering xanomeline transdermally. Examples of such
conditions associated with modulation of a muscarinic
receptor include, but are not in any way limited to decreased
cognition, Alzheimer's Disease, and severe painful
conditions. Preferred transdermal patch formulations include
but are not limited to a patch formulation comprising an
effective amount of xanomeline, azone, ethanol, water,
=
CA 02210711 1997-07-16
W 096/23463 PCTAUS96/00504
optionally propylene glycol and Klucel HF; an effective
amount of xanomeline intimately distributed in a matrix; an
effective amount of xanomeline and an acrylic adhesive; an
effective amount of xanomeline, ethanol, and Klucel HF;
described herein.
As reported herein, plasma levels were determined
using gas chromatography methods familiar to the skilled
artisan. The artisan can establish the appropriate
conditions for the gas chromatographic analysis; however, one
set of suggested conditions include the following:
A 30cm ~.25 ~um capillary column (J & W Scientific
for example); hydrogen flow rate of 3.2 ml/min, helium flow
rate of 14.3 ml/min, and air flow of 115.0 ml/min. The
gradient column temperature is suggested to be 90 to 270~ C,
detector at 250~C, and injector at 250~C. A suggested
detection type is nitrogen-phosphorus. The artisan will
recognize that other conditions will be effective as well;
however, the present conditions are provided as guidance to
assist the artisan in choosing the most desired parameters
for the present conditions.
Suitable enhancers may be additionally be alcohols
like 1,2 propane diol, 1,3 butylene glycol, l-hexadecanol, 2-
hydroxy fatty alcohols, 2-octyldodecanol, 2-propanol, benzyl
alcohol, cetylstearyl alcohol, diethylene glycol, dipropylene
glycol, dodecanol, ethanol, glycerol, hexanediol, octanol,
oleyl alcohol, panthenol, phenylcthanol, polyethylene
glycols, or polypropylene glycols, or fatty acids like capric
acid, linoleic acid, lauric acid, myristic acid, n-valerianic
acid, pelargonic acid, also other physiologically acceptable
low molecular acids like e.g. 3-phenylpropionic acid, acetic
acid, adipic acid, benzoic acid, salicyclic acid or their
skin compatible salts.
Similarly, sulphates and sulphonates of fatty
acids, like sodium cetylstearyl sulphate sodium lauryl
sulphate may be used advantageously. Esters of the formula
[CH3(CH2)mCOO]nR, in which m is an integer from 8 to 16,
CA 02210711 1997-07-16
W O 96/23463 PCTrUS5~'W504
preferably from 8 to 12; n is 1 or 2, preferably 1 and R is a
lower alkyl (Cl to C3 residue but also compounds like 1.3
diacetin, capric/caprylic triglyceride, diisopropyl adipate,
ethyl oleate, ethylene glycol (di-)stearate, ethylene glycol
monostearate, glycerol hydroxystearate, glycerol
monostearate, hydrogenated castor oil, oleic acid esters,
triacetin, alsophthalate esters like diethyl phthalate or,
di-(2-ethylhexyl)-phthalate may be added to the composition.
Other compounds with an advantageous action on the
drug substance skin flow include sulfoxides, e.g. dimethyl
sulfoxide or dodecylmethyl sulfoxide, amides like diethyl-m-
toluamide, dimethyl formamide, fatty acid diethanolamide, N2N
dimethyl acetamide, amines like diethanolamine or triethanol
amine, ethylene glycol derivatives like ethoxylated castor
oil, oleylalcohol/PEG-5-ether, glycerol ethers with
polyethylene glycol, diethylenglycol monomethylether,
diethylenglycol monoethylether, terpenes and terpenoids like
menthol, thymol, cineol, isobornyl acetate, limonene and
finally further compounds not belonging to a specific
chemical defined group but known to those skilled in the art
to be used for that purpose, e.g. dimethicon, squalen,
dimethyl isosorbide, lecithine, glycofurol, urea, N-methyl
pyrrolidone.
Acrylic Copolymers
Acrylic copolymers are understood to be more specifically
copolymers prepared from esters of acrylic acid and
methacrylic acid with Cl to Clg alcohols, dimethylaminoethanol
or other suitable alcoholic components, vinyl acetate, vinyl
pyrrolidone, styrene, butadiene, acryl nitrile or other
suitable compounds with a vinyl group.
The following examples are provided to more fully
illustrate the invention claimed herein. The examples are
provided for illustrative purposes only and are not intended
to limit the scope of the invention in any way.
CA 02210711 1997-07-16
W096/23463 PCT~S~6/00504
13xamDle 1
Transdermal formulation Free Base
A 0.5 g sample of xanomeline free base was
dissolved in 9.25 g of ethanol (200 proof). A 0.75 g sample
of azone and a 5.0 g aliquot of propylene glycol were added
to the ethanol mixture with stirring. A 10 g sample of water
was added to the mixture. The mixture was a cloudy
suspension. Finally, 0.75 g of Klucel was added to the
mixture and stirred until the Klucel was dispersed. The
mixture was allowed to stand for 24 hours. A 2.0 g sample of
the formulation prepared as described herein was dispensed by
syringe into a reservoir-type transdermal adhesive system.
Time Concentration in Dog
hours post a~lication na/ml Plasma
1 2 3 Mean + SEM
O O O 0 0+0
3 19 11 10 10.7+ 6.0
6 27 ~6 16 19.7+ 4.5
9 26 17 15 19.3+ 4.2
12 16 13 14 14.3+ 1.1
12 10 12 11.3+ 0.8
24 7 8 10 8.3+ 1.1
28 6 8 9 7.7+ 1.1
32 4 7 8 6.3+ 1.5
48 3 6 8 5.7+ 1.8
54 0 4 5 3.0+ 1.8
72 0 0 0 0+ 0
~xam~le 2
Transdermal Formulation without Polvethvlene Glvcol
A 0.5 g sample of xanomeline free base was
dissolved in 13.0 g of ethanol (200 proof). A 0.75 g sample
of azone was added to the ethanol mixture with stirring. An
11.25 g sample of water was added to the mixture. The
mixture was a clear solution. Finally, 0.75 g of Klucel was
CA 02210711 1997-07-16
W O 96/23463 PCTrU$96/00504
-10 -
added to the mixture and stirred until the Klucel was
dispersed. The mixture was allowed to stand for 24 hours. A
2.0 g sample of the formulation prepared as described herein
was dispensed by syringe into a reservoir-type transdermal
adhesive system.
Time Concentration in Dog
hours ~ost a~lication na/ml Plasma
1 2 3 Mean + SEM
0 ~ ~ ~ ~+~
3 19 12 4 11.7+ 5.3
6 24 17 6 15.7+ 6.4
9 18 11 4 11.0+ 4.9
12 12 9 5 8.7+ 2.5
9 8 3 6.7+ 2.3
24 6 5 3 4.7+ 1.1
28 9 ~ 0 4.3+ 3.2
32 7 3 0 3.3+ 2.5
48 3 0 3 2.0+ 1.2
54 0 0 0 0+ 0
72 0 0 0 0+ 0
Time Concentration in Mo~key
hours post a~lication n~/ml Plasma
1 2 3 Mean + SEM
O O , O 0 0+0
3 50 59 65 58+ 5.3
6 44 50 59 51+ 5.3
8 39 45 45 43i 2.5
12 25 42 41 36+ 6.7
34 37 22+ 11.8
24 14 13 16 14.3+ 1.1
28 . 12 8 8 9.3+ 1.6
32 9 7 7 7.7+ 0.8
48 5 5 4 4.7+ 0.4
54 2 2 2 2+ 0
72 0 0 0 0+ 0
CA 02210711 1997-07-16
W O 96/23463 PCTrUS96/OOS04
Patches were applied to the shaved chest of each rhesus
monkey.
ExamDle 3
Transdermal Xanomeline in Gel
A 1.0 g sample of xanomeline free base was
dissolved in 47.5 g of ethanol (200-proof). Then a 1.5 g
sample of Klucel gelling agent was added to the solution and
stirred until dispersed. The gel was allowed to stand for 24
hours. A 2.0 g sample of the formulation prepared as such
was dispensed by syringe into a reservoir-type transdermal
adhesive system.
The patches prepared as stated herein were applied
to rats. The rats were killed in pairs at various time
points after application and the rat brains were removed and
frozen. The binding of the Ml antagonist ligand, 3H-
pirenzepine, to muscarinic receptors in the brain was
determined. The decrease in binding is indicative of drug or
active metabolite present in the brain. The effect of the
drug after oral administration lasts less than 6 hours.
The percent of control ex vivo pirenzepine binding at 6 hours
was 33%, at 12 hours 15%, at 24 hours 26%, and at 48 hours
53%. The mean plasma concentration using this patch
formulation was as follows:
30 Time Mean Plasma Concentration (ng/ml) + SEM
6 109.8 + 35.53
12 152.4 + 30.18
24 115.9 + 43.02
48 28.07 + 5.995
CA 02210711 1997-07-16
W096/23463 PCT~S5~/0050q
~xamPle 4
Transdermal Xanomeline in Acrvlic Adhesive
A 600 mg sample of xanomeline free base was
dissolved in 41.6 g of pressure sensitive acrylic adhesive
(cat. number 80-1054, National Starch and Chemical
Corporation, Bridgewater, New Jersey 08807). The mixture was
agitated for 2 hours on a three roller mill. The mixture was
coated along the length of a 3 mil thick release liner using
a knife coater providing a 20 mil gap. The 20 mil gap
provides an effective 20 mil thick coating of the formulation
on the release liner. The sample was allowed to air dry for
24 hours. The sample was laminated on polyester backing.
The patches prepared as stated herein were applied
to rats. The rats were killed in pairs at various time
points after application and the rat brains were removed and
frozen. The binding of the M1 antagonist ligand, 3H-
pirenzepine, to muscarinic receptors in the brain was
determined. The decrease in binding is indicative of drug or
active metabolite present in the brain. The effect of the
drug after oral administration lasts less than 6 hours.
The percent of control ex vivo pirenzepine binding at 6 hours
was 101%, at 12 hours 89%, at 24 hours 75%, and at 48 hours
105%.
A transdermal xanomeline patch formulation in
acrylic adhesive was prepared substantially as described
supra; however, the patch formulation comprised 10.8 g
xanomeline per m2 (18% by weight) and 60 g of acrylic
adhesive per m2 (82% by weight). Individual 25 cm2 patches
were prepared to provide 27.2 mg of xanomeline free base per
patch. The patches were applied to the shaved abdomen of
rats and the shaved chest of monkeys. The patches were
removed at 24 hours.
CA 02210711 1997-07-16
W 096/23463 PCTrUS96/00504
Nean Plasma Concentration in Rat
Time(n~/ml) + SEM N-
1.004.635 + 1.750 3
2.007.198 + 0.986 3
4.0011.211 + 0.883 3
6.0010.398 + 1.251 3
8.008.261 + 1.193 3
10.009.576 + 0.000
15.0012.284 + 3.107 3
18.009.435 + 1.540 3
24.0010.870 + 0.319 3
30.000.522 + 0.268 3
Two such adhesive patches were applied to the
shaved chest of each monkey. The patches were removed at 24
hours.
Nean Plasma Concentration in Monk~y
Time(n~/ml) + SEM N
1.5025.750 + 2.160 3
3.0035.467 + 1.840 3
6.0031.070 + 2.352 3
9.0031.300 + 1.578 3
12.0030.230 + 3.413 3
24.0027.037 + 1.868 3
28.008.917 + 3.301 3
32.004.867 + 2.622 3
48.001.080 + 0.571 3
One such adhesive patch was applied to the chest of
each monkey. The patches were removed at 24 hours.
CA 022l07ll l997-07-l6
W 096/23463 PCTrUS~G/C~'01
-14-
Mean Plasma Conce~tration in Mo~key
Time (n~/ml) ~ SEM N
1.50 6.940 + 0.205 3
3.00 9.897 i 1.642 3
6.00 9.757 + 0.802 3
g oo 9.433 + 1.140 3
12.00 9.760 + 1.160 3
24.00 9.330 + 0.589 3
28.00 1.793 + 0.101 3
32.00 0.800 + 0.055 3
48.00 0.123 + 0.072 3
Exam~le 5
Trans~r~l Xanomeline in Acrvlic Adhesive
9.0g Xanomeline free base are dissolved in 91g of an acrylic
adhesive solution (solids content 50.0%, cat. number 901-
1052, National Starch & Chemical, Zutphen, The Metherlands).The mixture is stirred for at least 0.5 hours and is coated
on a 4 mil siliconized polyethylene terephthalate release
liner to provide a coated layer of 60 g/m2 (based on dried
matter). The wet layer is dried for 30 minutes at room
temperature, then for 10 minutes at 50 C. The sample was
laminated on a l-mil-backing layer of polyetylene
terephthalate.
Test samples of approximately 5 cm2 are punched for in vitro
skin permeation experiments on pig ear full thickness skin
(Franz type diffusion cell, at 37 C; phosphate buffer pH 4.4
as receptor fluid). A mean (n=3) cumulative permeated amount
of 46 ~g Xanomeline was found after 24 hours.
CA 02210711 1997-07-16
W O 96/23463 PCT~US96/00504
~XamDle 6
Transdermal Xanomeline in Ac~Ylic ~hecive
14.3g Xanomeline free base are dissolved in 85.7g of an
acrylic adhesive solution (solids content 50.0%, cat. number
901-1052, National Starch & Chemical, Zutphen, The
Netherlands).
The mixture is stirred for at least 0.5 hours and is coated
on a 4 mil siliconized polyethylene terephthalate release
liner to provide a coated layer of 60g/m2 (based on dried
matter). The wet layer is dried for 30 minutes at room
temperature, then for 10 minutes at 50~C. The sample was
laminated on a 1-mil-backing layer of polyethylene
terephthalate.
Test samples of approximately 5 cm2 are punched for in vitro
skin permeation experiments on pig ear full thickness skin
(Franz type diffusion cell, at 37~C; phosphate buffer pH 5.5
as receptor fluid). A mean (n=3) cumulative permeated amount
of 102 ~g Xanomeline was found after 24 hours.
Exam~le 7
Trans~err-l ~An~m~line in AcrYlic Adhesive
18.0g Xanomeline free base are dissolved in 82g of an acrylic
adhesive solution (solids content 50.0%, cat. number 901-
1052, National Starch & Chemical, Zutphen, The Netherlands).
The mixture is stirred for at least 0.5 hours and is coated
on a 4 mil siliconized polyethylene terephthalate release
liner to provide a coated layer of 60 g/m2 (based on dried
matter). The wet layer is dried for 30 minutes at room
temperature, then for 10 minutes at 50 C. The sample was
laminated on a 1-mil-backing layer of polymethacrylic
copolymer.
CA 022l07ll l997-07-l6
W 096123463 PCTrUS96/00~04
-16-
Test samples of approximately 5 cm2 are punched for in vitro
skin permeation experiments on pig ear full thickness skin
(Franz type diffusion cell, at 37 C; phosphate buffer pH 5.5
as receptor fluid). A mean (n=2) cumulative permeated amount
of 332 ,ug Xanomeline was found after 24 hours.
Examples 5 to 7 illustrate the dependence of xanomeline
permeation rate on the concentration o~ the drug.
According to Fick's law, one would expect a linear increase
in diffusion (and permeation ) rate with increasing drug
concentration. However, the following results based on the
examples show an unexpected increase.
Xanomeline Concentration in Permeated after 24 hours
dry adhesive matrix (% w/w) ~g/cm2
18 46 (Example
5)
28. 5 102 (Example
6)
36 332 (Example
7)
The values had been derived from clear solutions of the drug
in the adhesive. Unfortunately, the saturation limit of
about 23-28g6 (W/W) in this polymer limits the utilization of
this unexpected advantage of highly enriched xanomeline
preparations. It is concluded from this unexpected results
that an optimum formulation has to contain a slightly
subsaturated, saturated or even supersaturated amount of
xanomeline for best performance.
